PDL BioPharma inc (NASDAQ:PDLI) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
PDL BioPharma inc (NASDAQ:PDLI) lost -3.16 Percent and closed its previous trading session at $2.45. The stock traded with the average Volume of 1.59 Million at the end of last session.
PDL BioPharma inc (NASDAQ:PDLI) has the Market Capitalization of 371.98 Million. The Stock has its 52-week High of $3.55 and 52-Week Low of $2.27 and it touched its 52-week high on 10/23/17 and 52-Week Low on 06/28/18
The company reported its last earnings Actual EPS of $0.01/share. While, the analyst predicted that the company could provide an EPS of $0.09/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.08/share which shows an Earnings Surprise of -88.9 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated PDL BioPharma inc (NASDAQ:PDLI) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.87% where SMA50 and SMA200 are -3.67% and -11.75% respectively.
The company shows its Return on Assets (ROA) value of 8.6%. The Return on Equity (ROE) value stands at 12.6%. While it’s Return on Investment (ROI) value is 11.9%.
PDL BioPharma inc (NASDAQ:PDLI) currently has a Weekly Volatility of 3.48% percent while its Monthly Volatility is at 2.97% percent. While talking about Performance of the Stock, PDL BioPharma inc currently has a Weekly performance of -3.92%, monthly performance percentage is -3.54 percent, Quarterly performance is -14.04 percent, 6 months performance shows a percent value of 2.51% and Yearly Performance is -7.2 percent.
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.